Effect of natural menopause on serum levels of IGF-I and IGF-binding proteins: relationship with bone mineral density and lipid metabolism in perimenopausal women.

The present study was performed to examine the effect of natural menopause on serum levels of IGF-I, IGF-binding protein (IGFBP)-2 and -3 as well as on bone mass and lipid metabolism in perimenopausal women. One hundred and twenty-one healthy Japanese women, who were 45-55 years old, were studied (71 premenopausal and 50 postmenopausal women 1-9 years after menopause). Bone mineral density (BMD) was measured at the middle third of the radius by using dual energy X-ray absorptiometry. Serum levels of IGF-I, but not those of IGFBP-2 or -3, were significantly reduced in the postmenopausal group compared with the premenopausal group. One year after menopause, serum IGF-I levels were significantly lower, and the biochemical markers of bone turnover, such as serum total alkaline phosphatase level and urinary calcium to creatinine ratio, were significantly higher than the premenopausal levels. Serum levels of IGF-I, but not those of IGFBP-2 or -3, were positively correlated with BMD. Serum levels of IGFBP-2, but not those of IGF-I or IGFBP-3, were negatively correlated with body mass index and body weight. Finally, serum levels of IGFBP-3, but not those of IGF-I, were positively correlated with serum levels of total cholesterol and triglyceride. The present findings suggest that a rapid decrease in serum IGF-I levels after menopause might be partly involved in bone loss following gonadal failure and that IGFBP-2 and -3 might be related to the regulation of body mass and lipid metabolism during perimenopause respectively, although the mechanisms remain unknown.

[1]  M. Donath,et al.  Insulin-Like Growth Factor I , 1999, Drugs & aging.

[2]  C. Lang,et al.  Insulin-like growth factor-binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young. , 1995, The Journal of clinical endocrinology and metabolism.

[3]  C. Rosen,et al.  Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[4]  A. Forslund,et al.  Growth hormone‐dependent insulin‐like growth factor binding protein is a major determinant of bone mineral density in healthy men , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  G. Ciliberto,et al.  Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.

[6]  Kunihiko Ito,et al.  Increased Activity of Insulin‐like Growth Factor‐binding Protein in Human Thyroid Papillary Cancer Tissue , 1994, Japanese journal of cancer research : Gann.

[7]  M. Ranke,et al.  Decreased serum levels of insulin‐like growth factors and IGF binding protein 3 in osteoporosis , 1993, Journal of internal medicine.

[8]  R. Baxter.  Circulating binding proteins for the insulinlike growth factors , 1993, Trends in Endocrinology & Metabolism.

[9]  M. Blackman,et al.  Human growth hormone and human aging. , 1993, Endocrine reviews.

[10]  L. Raisz,et al.  Local and systemic factors in the pathogenesis of osteoporosis. , 1988, World review of nutrition and dietetics.

[11]  M. Blackman,et al.  Serum IGF-binding protein-3 is related to IGF-I, but not to spontaneous GH release, in healthy old men. , 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[12]  L. Carlsson,et al.  The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. , 1992, The Journal of clinical endocrinology and metabolism.

[13]  S. Ljunghall,et al.  Low plasma levels of insulin‐like growth factor 1 (IGF‐1) in male patients with idiopathic osteoporosis , 1992, Journal of internal medicine.

[14]  S. Ljunghall,et al.  Insulin-like growth factor I stimulates bone turnover in osteoporosis , 1992, The Lancet.

[15]  P. Langenberg,et al.  Insulin-like growth factor I and low-density-lipoprotein cholesterol in women during high- and low-fat feeding. , 1992, The American journal of clinical nutrition.

[16]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[17]  D. B. Evans,et al.  Recombinant human [Cys281]insulin-like growth factor-binding protein 2 inhibits both basal and insulin-like growth factor I-stimulated proliferation and collagen synthesis in fetal rat calvariae. , 1991, The Journal of biological chemistry.

[18]  D. Clemmons,et al.  Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. , 1991, The Journal of clinical endocrinology and metabolism.

[19]  R. Gambrell,et al.  Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. , 1991, American journal of obstetrics and gynecology.

[20]  H. Yamamoto,et al.  Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. , 1991, Acta endocrinologica.

[21]  K. Ho,et al.  Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[22]  M. Blackman,et al.  Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages. , 1991, The Journal of clinical endocrinology and metabolism.

[23]  C. Conover,et al.  Structural and biological characterization of bovine insulin-like growth factor binding protein-3. , 1990, Endocrinology.

[24]  G. Rodan,et al.  Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. , 1990, Endocrinology.

[25]  J. Devlin,et al.  The relationship between insulin-like growth factor-I, adiposity, and aging. , 1990, Metabolism: clinical and experimental.

[26]  H. Zeisel,et al.  A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. , 1990, The Journal of clinical endocrinology and metabolism.

[27]  M. Ranke,et al.  Insulin-like growth factor binding proteins (IGFBPs) with special reference to IGFBP-3. , 1990, Acta paediatrica Scandinavica. Supplement.

[28]  G. Rodan,et al.  Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. , 1989, Endocrinology.

[29]  E. Froesch,et al.  Release of insulin-like growth factor carrier proteins by osteoblasts: stimulation by estradiol and growth hormone. , 1989, Biochemical and biophysical research communications.

[30]  L. Avioli,et al.  Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Peacock,et al.  COMPARISON OF THE EFFECTS OF ORAL AND TRANSDERMAL OESTRADIOL ADMINISTRATION ON OESTROGEN METABOLISM, PROTEIN SYNTHESIS, GONADOTROPHIN RELEASE, BONE TURNOVER AND CLIMACTERIC SYMPTOMS IN POSTMENOPAUSAL WOMEN , 1989, Clinical endocrinology.

[32]  P Franchimont,et al.  Effects of repetitive administration of growth hormone-releasing hormone on growth hormone secretion, insulin-like growth factor I, and bone metabolism in postmenopausal women. , 1989, Acta endocrinologica.

[33]  K. Hall,et al.  Growth hormone treatment in short children: relationship between growth and serum insulin-like growth factor I and II levels. , 1987, The Journal of clinical endocrinology and metabolism.

[34]  A. Vermeulen.  Nyctohemeral growth hormone profiles in young and aged men: correlation with somatomedin-C levels. , 1987, The Journal of clinical endocrinology and metabolism.

[35]  S. M. Russell,et al.  Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Dawson-Hughes,et al.  Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. , 1986, The Journal of clinical endocrinology and metabolism.

[37]  D. Meldrum,et al.  Biologic effects of transdermal estradiol , 1986, The New England journal of medicine.

[38]  R L Hintz,et al.  Insulin-like growth factors I and II: aging and bone density in women. , 1984, The Journal of clinical endocrinology and metabolism.

[39]  E. Froesch,et al.  Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. , 1983, Endocrinology.

[40]  M. Kutner,et al.  Impaired growth hormone secretion in the adult population: relation to age and adiposity. , 1981, The Journal of clinical investigation.

[41]  W. Daughaday,et al.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. , 1980, The Journal of clinical endocrinology and metabolism.

[42]  S. Elek,et al.  Pituitary Growth Hormone Essential for Regulation of Serum Cholesterol , 1970, Nature.

[43]  K. Emerson.  Endocrinology and metabolism. , 1952, Medicine of the year.